Operating Lease, Right-of-Use Asset of Sarepta Therapeutics, Inc. from 01 Jan 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Sarepta Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 01 Jan 2019 to 31 Dec 2025.
  • Sarepta Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Dec 2025 was $125,495,000, a 15% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Sarepta Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $125,495,000 -$22,815,000 -15% 31 Dec 2025 10-K 02 Mar 2026 2025 FY
Q3 2025 $139,167,000 -$1,731,000 -1.2% 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $143,041,000 +$19,040,000 +15% 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $147,063,000 +$20,794,000 +16% 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $148,310,000 +$18,358,000 +14% 31 Dec 2024 10-K 02 Mar 2026 2025 FY
Q3 2024 $140,898,000 +$7,444,000 +5.6% 30 Sep 2024 10-Q 06 Nov 2024 2024 Q3
Q2 2024 $124,001,000 -$10,727,000 -8% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $126,269,000 +$64,253,000 +104% 31 Mar 2024 10-Q 01 May 2024 2024 Q1
Q4 2023 $129,952,000 +$64,998,000 +100% 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $133,454,000 +$90,420,000 +210% 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 $134,728,000 +$87,729,000 +187% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $62,016,000 +$16,034,000 +35% 31 Mar 2023 10-Q 02 May 2023 2023 Q1
Q4 2022 $64,954,000 +$19,423,000 +43% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $43,034,000 -$29,629,000 -41% 30 Sep 2022 10-Q 02 Nov 2022 2022 Q3
Q2 2022 $46,999,000 -$25,869,000 -36% 30 Jun 2022 10-Q 02 Aug 2022 2022 Q2
Q1 2022 $45,982,000 -$19,086,000 -29% 31 Mar 2022 10-Q 04 May 2022 2022 Q1
Q4 2021 $45,531,000 -$46,230,000 -50% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $72,663,000 +$1,578,000 +2.2% 30 Sep 2021 10-Q 03 Nov 2021 2021 Q3
Q2 2021 $72,868,000 -$1,329,000 -1.8% 30 Jun 2021 10-Q 04 Aug 2021 2021 Q2
Q1 2021 $65,068,000 +$1,971,000 +3.1% 31 Mar 2021 10-Q 05 May 2021 2021 Q1
Q4 2020 $91,761,000 +$53,828,000 +142% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $71,085,000 +$31,592,000 +80% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $74,197,000 +$34,748,000 +88% 30 Jun 2020 10-Q 05 Aug 2020 2020 Q2
Q1 2020 $63,097,000 +$21,999,000 +54% 31 Mar 2020 10-Q 06 May 2020 2020 Q1
Q4 2019 $37,933,000 -$4,567,000 -11% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $39,493,000 30 Sep 2019 10-Q 07 Nov 2019 2019 Q3
Q2 2019 $39,449,000 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $41,098,000 31 Mar 2019 10-Q 08 May 2019 2019 Q1
Q4 2018 $42,500,000 01 Jan 2019 10-K 01 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.